Revenue

Ditching the old OEM model for a 'win-win ecosystem,' Chery bets on shared tech and green manufacturing. A global summit will test this bold new vision.

As AI reshapes the job market, D Y Patil International University's HR Symposium reveals the new playbook for engineers: adaptability, soft skills, and lifelong learning.

Satair's new robotic warehouse in Singapore, powered by Swisslog's AutoStore, signals a major shift in aerospace supply chain strategy for the APAC region.

Orca Security partners with distributor TD SYNNEX, shifting its market strategy to rapidly expand access to its AI-powered, agentless cloud security platform.

New data shows Imofinostat turns 'cold' colorectal tumors 'hot' for immunotherapy and breaks chemo-resistance in pancreatic cancer, fueling pivotal trials.

IVY Rx unveils its 2026 compounded GLP-1 program with clear pricing, but operates in a market facing intense FDA warnings and regulatory uncertainty.

The market for at-home NAD+ therapy is booming, but as telehealth offers new convenience, it faces a wave of regulatory and safety questions.

Replimune halts a promising cancer therapy and cuts jobs after a stunning FDA rejection, citing a 'failed' system and inconsistent regulatory process.

Allogene Therapeutics faces a make-or-break moment as it prepares to unveil crucial trial data for its 'off-the-shelf' cancer therapy, cema-cel.

Investors watch Gibson Energy closely as it prepares for its Q1 results amid mixed performance, strategic acquisitions, and a changing energy landscape.

Amid a complex economy, DPC Dash is rapidly expanding, breaking global sales records and winning millions with a unique digital and cultural strategy.

Stephan Crétier, who turned a $25k loan into a $14B security empire, will keynote at SWGSB, offering bankers crucial lessons in risk and resilience.

MOVA AtomForm's new Palette 300 uses 12 nozzles and AI to promise waste-free, high-speed multi-color printing. But can it deliver on its bold claims?

Less than a year after its acquisition, Khoros launches Iris AI, an 'AI-native' platform aiming to unify customer engagement and unseat market leaders.

A jury found Abbott's Similac caused a fatal gut disease in premature infants, igniting a legal firestorm over what the formula giant knew and when.

A Chicago jury found Abbott liable for infants' injuries from Similac, adding to a wave of lawsuits over the deadly intestinal disease NEC.

Gensler's Andy Cohen joins the REIT's board, signaling a strategic shift toward design-led development in LA and Honolulu's premium real estate markets.

Novarad showcases its FDA-cleared VisAR system, an AR platform promising sub-millimeter accuracy and faster workflows for interventional radiology.

With a $2.135M financing round complete, Golden Shield Resources turns its focus to permitting its promising Marudi Mountain gold project in Guyana.

After sweeping awards, 'The Ebony Canal' takes its powerful message on Black maternal health from Hollywood to a global stage, aiming for systemic change.